Article

Allegro, Senju collaborate on integrin peptide therapy

Allegro Ophthalmics LLC and Senju Pharmaceutical Co. Ltd. have entered into a collaboration and agreement to develop and market Allegro’s integrin peptide therapy in Japan.

 

San Juan Capistrano, CA and Osaka, Japan-Allegro Ophthalmics LLC and Senju Pharmaceutical Co. Ltd. have entered into a collaboration and agreement to develop and market Allegro’s integrin peptide therapy in Japan.

With this collaboration, the companies aim to improve the quality of life for patients who continue to be at risk of blindness from vascular eye diseases by establishing integrin peptide therapy as the first‐in‐class treatment targeting integrin with an oligopeptide.

Under the terms of the agreement, Senju will acquire the rights to co‐develop and market Allegro’s integrin peptide therapy in Japan. In exchange for these rights, Senju has agreed to pay Allegro an upfront license fee, additional development and sales milestone fees, and a percentage royalty on net sales.

“The announcement of this partnership with Allegro further evidences Senju’s commitment to its position as a leader in ophthalmology in Japan,” said Shuhei Yoshida, executive vice president of Senju Pharmaceutical. “We believe that Allegro’s integrin peptide therapy shows great promise as a first‐in‐class treatment for wet age-related macular degeneration, diabetic macular edema, and other vascular eye indications, and we are eager to begin the process for regulatory approval in Japan.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.